What CLIA-waived means

CLIA regulates facilities that test human specimens for health assessment or for the diagnosis, prevention, or treatment of disease. Within that framework, the FDA categorizes diagnostic tests by complexity as waived, moderate complexity, or high complexity. A test categorized as waived is generally simple to use, carries a low risk of inaccurate results, and is suitable for settings that don't have the infrastructure of a full clinical laboratory.

It's important to note that "waived" does not mean "error-proof." Waived testing can still produce errors when users don't follow the manufacturer's instructions or when personnel are unfamiliar with the test system. That distinction matters for buyers and sellers alike — the value of a waived product depends not only on the product design, but also on proper storage, training, and adherence to the instructions for use.

Who makes a product CLIA-waived

A manufacturer can't make its own product CLIA-waived by declaration alone. The FDA is the agency that categorizes a test's complexity, including whether it's waived, after reviewing the relevant submission and evidence. CMS then regulates the testing site through the CLIA certificate structure, which determines whether that site is authorized to perform waived testing.

There are several paths by which a product becomes CLIA-waived. Some tests are automatically categorized as waived because they're approved for home or over-the-counter use, or because they're waived by regulation. For other tests, the manufacturer must seek a CLIA Waiver by Application from the FDA after the test has been categorized, or pursue a dual submission that combines a 510(k) premarket notification with a CLIA waiver request — a pathway the FDA describes as supporting both market clearance and waived status at the same time, for tests that are simple to use and carry a low risk of inaccurate results.

FDA

Categorizes a test's complexity and decides whether it qualifies as waived.

CMS

Regulates the testing site itself through the CLIA certificate structure.

Certificate of Waiver

The certificate a site must hold to legally perform CLIA-waived testing.

Which groups use CLIA-waived products

CLIA-waived products are used most often by organizations that want to test near the patient or in decentralized healthcare settings rather than in a central laboratory. Common users include physician offices, urgent care centers, retail clinics, pharmacies, school-based or community clinics, occupational health sites, and other point-of-care environments that hold a CLIA Certificate of Waiver. Home users may also use some waived tests when the FDA has authorized the product for home or over-the-counter use.

Drug and alcohol testing adds an important distinction. CLIA applies when testing of human specimens is performed for diagnosis, treatment, or other clinical health purposes. By contrast, testing performed solely for employment, insurance, or forensic purposes is generally outside CLIA's scope, even though the product itself may still be marketed as CLIA-waived for clinical settings. This is why the same style of rapid test can be relevant to both healthcare buyers and workplace-testing buyers, but for different compliance reasons.

Why buyers want CLIA-waived products

The main reason organizations seek CLIA-waived products is operational simplicity. A waived test can be used in facilities with a Certificate of Waiver rather than a more demanding moderate- or high-complexity laboratory certification, making it easier for smaller sites to add testing services. This lowers barriers to implementation and supports faster testing closer to the patient.

Speed and convenience are also major drivers. Waived products are often used in point-of-care settings because they let staff obtain results during the patient encounter, which can improve workflow and support quicker clinical decisions. In many settings, that means fewer send-outs to outside labs, less delay, and a better patient or customer experience.

Finally, buyers value CLIA-waived products because they broaden access. Clinics, pharmacies, schools, and satellite care sites may not have the personnel or infrastructure required for nonwaived testing, but they can still provide useful diagnostic screening when a test is categorized as waived and performed under the proper certificate. For product marketers, this makes CLIA-waived status commercially important because it expands the range of eligible use sites while signaling ease of use and lower testing complexity.